IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 1633

MCLACHLAN et al.

Art Unit: 1646

Appl. No.: 10/535,458

Examiner: To Be Assigned

Filed: November 20, 2003

Atty. Docket: 2159.0640005/EKS/PAC/DLL

For: Novel Gene Targets and Ligands
That Bind Thereto for Treatment
and Diagnosis of Colon Carcinomas

Supplemental Preliminary Amendment Under 37 C.F.R. § 1.115 and Response to Notification of Defective Response

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

Amendments to the Specification begin on page 2 of this paper.

Remarks and Arguments begin on page 3 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.